Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by garygpon Aug 27, 2021 11:49am
134 Views
Post# 33775886

RE:RE:RE:RE:RE:anyone ordered the immusafe test yet?

RE:RE:RE:RE:RE:anyone ordered the immusafe test yet?I'm thinking ProMIS will take anything it can get by way of revenue and scientific recognition, but the real deal for them is still AD.  Don't get me wrong, serology will not be swept under the mat but this is not where PMN want to spend their time or resources.

With the FSG now firmly in PMN's camp and the current financing completed, I can see where AD will be full steam ahead.

Now all we have to do is buckle up and wait for the inevitible share consolidation and see how badly the old guard get hosed. 

Goldstein and the BOD should be ashamed of themselves collectively for allowing shareholders to have been taken to the cleaners the way we have been, but they won't be.  When it comes to shame, it doesn't exist for them; Greed, power and "their" personal wealth is far more important to them than anything.  Self preservation and their wealth at any cost is an excellent grease to lubricate the big wheel(s).
<< Previous
Bullboard Posts
Next >>